fusion inhibitor


Also found in: Medical, Wikipedia.
Related to fusion inhibitor: protease inhibitor, Integrase inhibitor

fusion inhibitor

n.
Any of a class of drugs that interfere with the entry of HIV into helper T cells by inhibiting the fusion of the viral and cell membranes.
Mentioned in ?
References in periodicals archive ?
To potently inhibit HIV-1 entry, a C-HR targeting fusion inhibitor can have a relatively low affinity, but an N-HR targeting fusion inhibitor must bind extremely tightly.
In January, new precautions were added to the labeling for the injectable HIV fusion inhibitor Fuzeon.
The fusion inhibitor already on the market--enfuvirtide, developed in 2003 by Roche and Trimeris under the brand name Fuzeon--has proven effective, but many HIV-positive patients are turned off by its high cost and the fact that it must be injected with a syringe.
The approval of the fusion inhibitor T-20 (enfuvirtide, Fuzeon) now means that there are 4 classes of drugs available.
Enfuvirtide, a novel HIV-1 fusion inhibitor, had significant antiretroviral and immunologic effects when added to an otherwise optimized treatment regimen in patients with multidrug-resistant HIV-1 infection in an open-label randomized, controlled trial.
The third drug, called T-1249, is a fusion inhibitor that binds to the viral protein that forms a shell around HIV.
A second-generation fusion inhibitor, T-1249, is currently being evaluated in Phase I clinical studies.
Today's conditional marketing authorisation in the European Union of the new protease inhibitor (PI) darunavir (boosted with ritonivir) provides physicians with the opportunity to build a potent new treatment combination with the fusion inhibitor, FUZEON.
Currently he's on what's known as a "salvage" regimen that includes a boosted protease inhibitor and the injectable fusion inhibitor Fuzeon--drugs he can't give up if he hopes to keep his virus under control.
9 /PRNewswire-FirstCall/ -- New data presented in an oral session at the 13th Conference on Retroviruses and Opportunistic Infections (CROI) this week support the continued development of two next-generation HIV fusion inhibitor peptide candidates, Roche and Trimeris, Inc.
A fusion inhibitor, the compound is a 36-amino-acid peptide that will require subcutaneous injection.
Studies have shown that darunavir, when used in combination with the fusion inhibitor FUZEON, can substantially increase the chances of reaching undetectable viral load - the new treatment goal in HIV.